Antimutagenicity protection of Ginkgo biloba extract (Egb 761) against mitomycin C and cyclophosphamide in mouse bone marrow.
Genet Mol Res
; 8(1): 328-33, 2009 Mar 24.
Article
en En
| MEDLINE
| ID: mdl-19440968
ABSTRACT
Ginkgo biloba (Egb 761) extract, the most prescribed phytomedicine in Europe for the treatment of cerebral insufficiency and vascular diseases, was tested for its possible protective effects against mitomycin C (MMC)- and cyclophosphamide (CP)-induced mutagenicity using the micronucleus test in mouse bone marrow. The extract was co-administered to mice at doses of 50, 100 and 200 mg/kg (po) with 4 mg/kg (ip) MMC or 24 mg/kg (ip) CP. All doses of Egb 761 were significantly (P < 0.05) effective in reducing the frequency of micronucleated polychromatic erythrocytes, when compared with MMC or CP alone. Based on these results, we suggest that Egb 761 possesses both direct and indirect antimutagenic potential.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Médula Ósea
/
Extractos Vegetales
/
Mitomicina
/
Antimutagênicos
/
Ciclofosfamida
/
Mutágenos
Límite:
Animals
Idioma:
En
Revista:
Genet Mol Res
Asunto de la revista:
BIOLOGIA MOLECULAR
/
GENETICA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Brasil